Literature DB >> 17854979

In vitro evaluation of dual mode ultrasonic thrombolysis method for transcranial application with an occlusive thrombosis model.

Zuojun Wang1, Mark A Moehring, Arne H Voie, Hiroshi Furuhata.   

Abstract

A recent clinical trial of transcranial low-frequency ultrasound-mediated tPA thrombolysis (LFUT) showed cerebral hemorrhages associated with high spatial peak pulse average intensity (I(SPPA)), wide beam and long pulse duration. We developed an alternative approach to LFUT wherein diagnostic power M-mode Doppler (PMD) ultrasound is combined with LFUT, with a goal of increased safety. The effectiveness of such a dual mode ultrasonic thrombolysis (DMUT) was explored in vitro. The DMUT system emitted PMD (2 MHz) and LFUT (550 kHz) beams in alternating fashion from a small 12 mm diameter probe. The LFUT had a low I(SPPA) (2 W/cm(2)) and a short pulse duration (55 micros). Occlusive clots made in plastic tips from bovine plasma and thrombin were placed in flow models pressurized to 800 mH(2)O, with 600 IU/mL monteplase injected upstream. Recanalization times were then compared among three groups: the control (monteplase alone), PMD (monteplase + PMD) and DMUT (monteplase + PMD + LFUT). The capability of the DMUT device to monitor recanalization was demonstrated by observing with Doppler the degree of flow of a blood-mimicking fluid in the vicinity of the clot. Recanalization times were 37.9 +/- 22.9, 38.9 +/- 12.4 and 18.5 +/- 8.0 min, respectively, for the control, PMD and DMUT. There were significant differences between DMUT and the control (p = 0.0004) and between DMUT and PMD (p = 0.0004). Recanalization flows were clearly detected. It is anticipated that this DMUT method presents a safer and more efficient approach than normal LFUT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854979     DOI: 10.1016/j.ultrasmedbio.2007.07.010

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  7 in total

1.  Investigation of standing-wave formation in a human skull for a clinical prototype of a large-aperture, transcranial MR-guided focused ultrasound (MRgFUS) phased array: an experimental and simulation study.

Authors:  Junho Song; Aki Pulkkinen; Yuexi Huang; Kullervo Hynynen
Journal:  IEEE Trans Biomed Eng       Date:  2011-10-28       Impact factor: 4.538

Review 2.  [Therapeutic ultrasound of acute cerebral artery occlusion].

Authors:  M Nedelmann; T Gerriets; M Kaps
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

3.  In silico study of low-frequency transcranial ultrasound fields in acute ischemic stroke patients.

Authors:  Guillaume Bouchoux; Ravishankar Shivashankar; Todd A Abruzzo; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2014-03-14       Impact factor: 2.998

4.  Intracranial Non-thermal Ablation Mediated by Transcranial Focused Ultrasound and Phase-Shift Nanoemulsions.

Authors:  Chenguang Peng; Tao Sun; Natalia Vykhodtseva; Chanikarn Power; Yongzhi Zhang; Nathan Mcdannold; Tyrone Porter
Journal:  Ultrasound Med Biol       Date:  2019-05-15       Impact factor: 2.998

5.  Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.

Authors:  Madhuvanthi A Kandadai; Jason M Meunier; Kimberley Hart; Christy K Holland; George J Shaw
Journal:  Transl Stroke Res       Date:  2014-11-20       Impact factor: 6.829

6.  Experimental validation of a finite-difference model for the prediction of transcranial ultrasound fields based on CT images.

Authors:  Guillaume Bouchoux; Kenneth B Bader; Joseph J Korfhagen; Jason L Raymond; Ravishankar Shivashankar; Todd A Abruzzo; Christy K Holland
Journal:  Phys Med Biol       Date:  2012-11-15       Impact factor: 3.609

7.  Accelerated sonothrombolysis with Definity in a xenographic porcine cerebral thromboembolism model.

Authors:  Robert T Kleven; Kunal B Karani; Nicole Hilvert; Samantha M Ford; Karla P Mercado-Shekhar; John M Racadio; Marepalli B Rao; Todd A Abruzzo; Christy K Holland
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.